Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2026-06-03 Board/Management Inform…
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Current Report on Form 8-K filed under Item 5.02, announcing the resignation of the Chief Accounting Officer and the appointment of a new principal accounting officer. This is a clear announcement of senior management changes, fitting the Board/Management Information category.
2026-06-03 English
FORM 8-K
Board/Management Information Classification · 93% confidence The document is a Form 8-K Current Report under the Securities Exchange Act, specifically disclosing the departure of the Chief Medical Officer and the appointment of an interim Chief Medical Officer. These are announcements of senior management changes, matching the Board/Management Information category.
2026-05-14 English
FORM 8-K
Regulatory Filings
2026-05-14 English
8-K - Ocugen, Inc. (0001372299) (Filer)
Regulatory Filings Classification · 89% confidence The submitted document is a Form 8-K "Current Report" filed with the U.S. SEC, containing Items 2.02 (Results of Operations and Financial Condition) and 8.01 (Other Events including pricing of a private convertible notes offering). It is not the primary earnings press release itself nor a standalone financing announcement, but rather the regulatory filing reporting these events. Therefore, it should be classified under the catch-all “Regulatory Filings” category.
2026-05-05 English
8-K - Ocugen, Inc. (0001372299) (Filer)
Capital/Financing Update Classification · 90% confidence The document is a U.S. SEC Form 8-K current report dated May 4, 2026, disclosing the Company’s intention to offer $115 million of convertible senior notes due 2034 in a private placement and explaining preliminary unaudited financial information in connection with that offering. This constitutes a fundraising/financing activity. There is no indication it is an earnings release, management discussion, or audit report. It is an announcement of a capital financing transaction, fitting the Capital/Financing Update category.
2026-05-04 English
ARS - Ocugen, Inc. (0001372299) (Filer)
Annual Report
2026-04-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.